Roman Schimmer

Hematology Physician scientist @UZH_en & @Unispital_USZ | particular interest in myeloid malignancies

[Mohamad Mohty @Mohty_EBMT]

To the incredible healthcare professionals who remained behind to care for patients while your colleagues attended the #ASH24 congress in San Diego, we extend our deepest gratitude. Your dedication and selflessness ensure that patient care remains a constant priority, even as the field advances through events like this #ASH24 . Thank you for your compassion, and for keeping the heart of healthcare beating strong.
@ASH_hematology @TheIACH @COMyCongress @Mohty_EBMT

[Boettcher Lab @TheBoettcherLab]

Congratulations to #Jonas Fullin from my lab @Unispital_USZ @UZH_en @CCCZ_USZ presenting his data on #TP53 allelic states in #AML #ASH24 @ASH_hematology 👏🎉

[Roman Schimmer @RomanSchimmer]

@NicoGagelmann PCH

[University of Zurich @UZH_en]

If patients with aggressive blood cancer have a certain mutation, novel immunotherapies do not work. Researchers from @UZH_en and @Unispital_USZ have discovered this mechanism – and found ways to overcome the resistance. Acute myeloid #leukemia (AML)
https://t.co/tJE25prRmN

[EMBO Mol. Medicine @EmboMolMed]

Our March issue is online! 🌺
This month's cover by @DrawImpacts highlights the article by @TheBoettcherLab that shows that TP53 mutations in #AML confer resistance to #CARTcell therapy

➡️https://t.co/6v8G0xA6Wl

[Boettcher Lab @TheBoettcherLab]

!!! PAPER OUT in @EmboMolMed !!!
#TP53-mutant #AML is notoriously hard to treat. Immunotherapies might be a promising therapeutic option. Ever wondered what the impact of the #TP53-mutational status on #CARTCell efficacy in AML is? https://t.co/QY8AeO8nGQ A 🧵1/n

[British Journal of Haematology @BrJHaem]

Authors report the successful and safe off-label administration of caplacizumab during pregnancy and urgent delivery in a patient with refractory iTTP
https://t.co/4eNEtJB1xT
@RomanSchimmer

[Roman Schimmer @RomanSchimmer]

@grichardmd @Dr_AmerZeidan @MikkaelSekeres @DanielleHammo20 @sanamloghavi @Ramikomrokji @GMontalbanBravo @garciamanero Would go for HSCT, even more so since Len has been shown to select for TP53 mutants

[Roman Schimmer @RomanSchimmer]

@nihardesai7 @BrownJHM @nihar_nayak2 @DoctorBhavsar @chandrachud_n @Nischistocyte @Dishaar88241487 @adiv2711 @HemOncFellows @MorphologyAmigo @HaemBytes Vyxeos - liposomal daunorubicin & cytarabine

[Roman Schimmer @RomanSchimmer]

@DocsDock200 IgM against I

[Roman Schimmer @RomanSchimmer]

@BloodJournal @benoit_tobias

[Boettcher Lab @TheBoettcherLab]

Congrats @RomanSchimmer on his dual achievement: First-author paper"#TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms" published in @BloodAdvances & his doctoral degree. Well done, Dr. Schimmer! @UZH_en @Unispital_USZ @CCCZ_USZ